3. (Amended) The therapeutic agent according to claim 1 or 2, wherein the therapeutic agent for hypercalcemia is chosen from at least one of a bone resorption-inhibiting agent, a calcium excretion-promoting agent, an agent for inhibiting intestinal absorption of calcium, and a loop diuretic.

5. (Amended) The therapeutic agent according to claim 4, wherein the bone resorption-inhibiting agent is at least one of bisphosphonate or calcitonin.

6. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the active ingredient is an antagonist for the PTHrP receptor.

7. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the active ingredient is an anti-PTHrP antibody.

8. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the active ingredient is a fragment of an anti-PTHrP antibody and/or a modified form of the fragment.

10. (Amended) The therapeutic agent according to claim 7, wherein the antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

13. (Amended) The therapeutic agent according to any one of claims 1 or 2, wherein the drug-resistant hypercalcemia is caused by cancer.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Please add new claims 14-16 as follows:

13. (New) The therapeutic agent according to claim 5, wherein the active ingredient is chosen from at least one of

a) an antagonist for the PTHrP receptor;

b) an anti-PTHrP antibody;

c) a fragment of an anti-PTHrP antibody and/or a modified form of the fragment.

15. (New) The anti-PTHrP antibody of claim 14, wherein antibody is chosen from at least one of a human antibody, a humanized antibody, and a chimeric antibody.

16. (New) The therapeutic agent according to claim 5, wherein the drug-resistant hypercalcemia is caused by cancer.

REMARKS

Claims 1-16 are now pending in this application. Applicants have filed this Preliminary Amendment to ensure that the pending claims meet with U.S. practice requirements. Specifically, Applicants have eliminated improper multiple dependency and clarified grammar in the claims. New claims 14, 15, and 16 are based on claims 6-8, 10, and 13, respectively. These new claims were added to replace subject matter cancelled to eliminate improper multiple dependency and thus do not add any new matter to the application.

These Amendments do not change the scope of the claims in any way and are not substantive, but are only made to more particularly define the invention and conform with U.S. requirements on multiple dependency. Applicants request the consideration of this application and examination of these claims.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com